Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs).
Paul Hamberg
No relevant relationships to disclose
Marye Boers-Sonderen
No relevant relationships to disclose
Walter J. Loos
No relevant relationships to disclose
Maja J. De Jonge
No relevant relationships to disclose
Winette T.A. Van Der Graaf
No relevant relationships to disclose
Ben B Suttle
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Ferry Eskens
No relevant relationships to disclose
Jaap Verweij
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline
Carla Van Herpen
No relevant relationships to disclose
Stefan Sleijfer
Research Funding - GlaxoSmithKline